Kelyniam Global Reports 2025 Financial Results

Rhea-AI Summary

Kelyniam Global (OTC: KLYG) reported 2025 results showing an 85% improvement in net loss to $(138,555) and total revenue of $3,053,222, down 8% year-over-year. The company recorded an operating loss of $(96,449) and EBITDA of $(81,661).

Kelyniam secured FDA 510(k) clearance for Fusion™ cranial implants using VESTAKEEP Fusion (PEEK+BCP) and said Fusion™ implants can be delivered within 24–48 hours. The board declined an unsolicited transaction indication as materially inadequate and will continue evaluating strategic opportunities to enhance shareholder value.

Positive

• Net loss improved by 85% to $(138,555)
• FDA 510(k) clearance granted for Fusion™ cranial implants
• Fusion™ implants deliverable within 24–48 hours

Negative

• Operating loss of $(96,449) vs prior operating income $277,037
• EBITDA negative at $(81,661)

Strong Second-Half Momentum Drives 85% Net Loss Improvement; FDA Clearance Secured for Innovative Fusion™ Biomaterial Implant; Board Rejects Undervalued Acquisition Interest

CANTON, Conn., March 16, 2026 /PRNewswire/ -- Kelyniam Global (OTC: KLYG), a leader in custom cranial implants, today announced its financial results for the year ended December 31, 2025.

"Despite a challenging start to last year, our team delivered a strong rebound in the second half while achieving meaningful bottom-line progress through continued expense management," said Ross Bjella, CEO of Kelyniam Global. "We are especially pleased with the 85% improvement in net loss, reflecting the strength of our core business model, the elimination of prior-year one-time charges, and sales across our innovative product portfolio. These results demonstrate our ability to respond to market conditions and we remain confident in our path forward."

Financial Highlights (Year ended December 31, 2025 vs. December 31, 2024)

• Total revenue of $3,053,222, an 8% decrease from $3,328,384, with solid recovery in the latter half of the year,
• Gross profit of $2,387,283 compared to $2,594,137
• Operating loss of $(96,449) compared to operating income of $277,037,
• Net loss of $(138,555), an 85% improvement from $(920,206)
• EBITDA of $(81,661) compared to $322,824

The Company received FDA 510(k) clearance for our Fusion™ cranial and craniofacial implants, the first to utilize VESTAKEEP® Fusion—a next-generation biomaterial combining PEEK with biphasic calcium phosphate (BCP). This pioneering material leverages the proven mechanical strength, biocompatibility, and radiolucency of PEEK while incorporating BCP's osteoconductive properties to promote enhanced bone cell attachment, accelerated osteointegration, and improved bone regrowth at the implant interface.  The Fusion™ implants use Kelyniam's patented integrated fixation system and can be delivered within 24-48 hours.

In late 2025, Kelyniam received unsolicited interest from a third party regarding a transaction regarding the Company. After careful consideration, the Company determined the preliminary cash and stock indication of enterprise value was materially inadequate and did not reflect the full value of the Company's assets, technology, and long-term growth potential, and therefore elected to not pursue further discussions at that time.  The Company remains committed to evaluating opportunities that support the Company's long-term strategy and enhance shareholder value.

About Kelyniam

Kelyniam Global, Inc. specializes in the rapid production of custom prosthetic cranial implants utilizing computer-aided design and computer-aided manufacturing of advanced medical-grade polymers. The Company develops, manufactures, and distributes custom cranial and craniofacial implants for patients requiring reconstruction. Kelyniam works directly with surgeons, health systems, and payors to improve clinical and cost-of-care outcomes. The Company's website is www.Kelyniam.com.

As a cautionary note to investors, certain matters discussed in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; the Company's ability to execute its service and product sales plans; changes in the status of ability to market products; and the risks described from time to time in the Company's SEC reports.

View original content:https://www.prnewswire.com/news-releases/kelyniam-global-reports-2025-financial-results-302713625.html

SOURCE Kelyniam Global Inc

FAQ

What were Kelyniam Global (KLYG) full-year 2025 financial results?

Kelyniam reported 2025 revenue of $3,053,222 and a net loss of $(138,555). According to the company, net loss improved 85% year-over-year driven by second-half momentum and expense management.

What does the FDA 510(k) clearance mean for Kelyniam (KLYG) Fusion™ implants?

FDA 510(k) clearance allows Fusion™ cranial implants to be marketed in the U.S. According to the company, Fusion™ uses VESTAKEEP Fusion (PEEK+BCP) and aims to promote faster osteointegration and bone regrowth at the implant interface.

How quickly can Kelyniam (KLYG) deliver Fusion™ cranial implants after clearance?

Kelyniam can deliver Fusion™ implants within 24–48 hours. According to the company, the implants use a patented integrated fixation system designed for rapid manufacturing and expedited clinical delivery timelines.

How did Kelyniam (KLYG) operating results change in 2025 versus 2024?

Kelyniam posted an operating loss of $(96,449) in 2025 versus operating income of $277,037 in 2024. According to the company, second-half recovery improved results but did not offset earlier-year setbacks.

Why did Kelyniam (KLYG) decline the unsolicited acquisition indication in late 2025?

Kelyniam said the preliminary cash and stock indication materially undervalued the company. According to the company, the offer did not reflect the full value of its assets, technology, and long-term growth potential.

What are the near-term financial priorities for Kelyniam Global (KLYG)?

Kelyniam prioritizes expense management and commercial rollout of Fusion™ implants after FDA clearance. According to the company, focus remains on sustaining second-half momentum and evaluating strategic opportunities to enhance shareholder value.